EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Iron and Cancer

Suzy V Torti, Lia Tesfay, Frank M Torti

Advances in Experimental Medicine and Biology · 2025

DOI: 10.1007/978-3-031-92033-2_18 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Experimental Medicine and Biology, 2025. Verfasst von Suzy V Torti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Biophysics, UConn Health, Farmington, CT, USA. storti@uchc.edu. Hauptthemen laut MEDLINE: Neoplasms, Iron. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron is required for numerous essential processes, including DNA synthesis, DNA repair, and cellular metabolism. Cancer cells frequently demonstrate an enhanced demand for iron when compared to slowly cycling non-cancer cells due to their increased reliance on these processes. Manifestations of this demand include up-regulation of iron import, decrease in iron export, alterations in iron intracellular trafficking, as well as alterations in "iron gene" expression signatures that can predict prognosis. Cells of the tumor microenvironment, including T cells, tumor-associated macrophages, and cancer-associated fibroblasts, crosstalk with tumor cells to further modulate tumor iron status. Dietary iron, particularly heme iron, has been associated with increased cancer risk, although the influence of iron on immune cells of the microenvironment may modulate this risk. Tumor cell reliance on iron creates therapeutic opportunities. For example, the excess iron accumulated by cancer cells renders them susceptible to agents that induce ferroptosis, an iron-dependent form of cell death. In addition, significant progress has been made in the design of agents to target tumor cell iron dependence in other ways, including small molecule iron chelators and agents that target iron uptake, some of which are in current clinical trials. Recent discoveries, such as the key role of iron recycling in KRAS-mutated pancreatic cancer, are expected to further accelerate the transition of such agents to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsIronHumansTumor MicroenvironmentAnimalsFerroptosisIron Chelating Agents

Stichwörter der Autor:innen

FerroptosisIron chelation therapyIron metabolism in cancerIron-dependent enzymesTumor microenvironment

Substanzen

IronIron Chelating Agents

Autor:innen und Institutionen

  • Department of Molecular Biology and Biophysics, UConn Health, Farmington, CT, USA. storti@uchc.edu.
  • Department of Molecular Biology and Biophysics, UConn Health, Farmington, CT, USA.
  • Department of Medicine, UConn Health, Farmington, CT, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Torti, S. V., Tesfay, L., & Torti, F. M. (2025). Iron and Cancer. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-3-031-92033-2_18

Vancouver

Torti SV, Tesfay L, Torti FM. Iron and Cancer. Advances in Experimental Medicine and Biology. 2025. doi:10.1007/978-3-031-92033-2_18

BibTeX
@article{Torti2025,
  author = {Torti, Suzy V and Tesfay, Lia and Torti, Frank M},
  title = {Iron and Cancer},
  journal = {Advances in Experimental Medicine and Biology},
  year = {2025},
  doi = {10.1007/978-3-031-92033-2_18}
}
Kostenlos starten →